I am pleased that Kerner and Völzke ([@B1]) believe, based on their experience and assumptions, that the death rate from hypoglycemia in their patients with type 1 diabetes is lower than in the published literature. In my commentary ([@B2]) on the report of McCoy et al. ([@B3]) of a 3.4-fold higher mortality in patients with diabetes who self-reported severe hypoglycemia 5 years earlier, I cited four relatively recent series (all cited specifically in ref. [@B4]) reporting that 4, 6, 7, and 10% of deaths of people with type 1 diabetes were attributed to hypoglycemia. Those proportions do not require any assumptions aside from the accuracy of the attributions. They are generally higher than the proportions of 2--4% of deaths reported in three earlier series (all also cited specifically in ref. [@B4]), and are of even greater concern in view of the increasing life expectancy of individuals with type 1 diabetes ([@B5]). Given those published data---4% = 1 in 25 and 10% = 1 in 10---I concluded ([@B2]) that "it is sobering to think that as many as 1 in 25---or even 1 in 10---patients with type 1 diabetes will die of iatrogenic hypoglycemia. Obviously, life-threatening episodes of hypoglycemia need not be frequent to be devastating." Whatever the precise hypoglycemic mortality rate, I think all who care for people with diabetes should consider these data ([@B4]).
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